Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) has shared an announcement.
Jiangxi Rimag Group Co., Ltd reported a significant increase in its interim results for the first half of 2025, with a 12.9% rise in revenue and a 1,545.9% increase in profit compared to the same period in 2024. This growth was driven by an expanding customer base and strategic initiatives, including the development of new imaging centers and the introduction of an asset-light empowerment business model. The company also made strides in AI-driven business innovation, leveraging partnerships to enhance its medical data capabilities.
The most recent analyst rating on (HK:2522) stock is a Buy with a HK$52.39 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
More about Jiangxi Rimag Group Co., Ltd. Class H
Jiangxi Rimag Group Co., Ltd is a leading medical group in China specializing in medical imaging. It operates a medical imaging platform that offers diversified imaging services across the entire medical imaging industry chain.
Average Trading Volume: 15,369,456
Technical Sentiment Signal: Hold
Learn more about 2522 stock on TipRanks’ Stock Analysis page.